Novel method for monitoring of carcinogenic impurity of N‐nitrosamine in nizatidine pharmaceutical products using ultra high‐pressure liquid chromatography triple quadrupole mass spectrometry
Rapid Communications in Mass Spectrometry · 2024
DOI: 10.1002/rcm.9884 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2024. Verfasst von Shivani Dhorajiya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, Gujarat, India. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Nizatidine, Drug Contamination, Nitrosamines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Gujarat Technological University.
Abstract (Originalsprache)
Nitrosamine compounds pose a significant concern as potential carcinogens, prompting heightened scrutiny from regulatory bodies, particularly regarding their presence in pharmaceuticals. The detection of unacceptable levels of N‐nitrosodiethylamine (NDMA) in ranitidine has led to widespread recalls, driving interest in alternative medications such as nizatidine, which shares a similar pharmacological class and is used to treat various gastrointestinal conditions. Despite fewer reports on NDMA levels in nizatidine, its structural similarity to ranitidine, characterized by a tertiary amine, underscores the potential for NDMA formation. Addressing the analytical challenges associated with nitrosamine detection, this study focuses on developing and validating an ultra‐high pressure liquid chromatography triple quadrupole mass spectrometry (UHPLC–MS/MS) method for quantifying NDMA in both nizatidine active pharmaceutical ingredients and tablet formulations. Method validation adheres to International Council for Harmonisation recommendations, with a demonstrated linear range of 0.25–100 ng/mL for NDMA, exhibiting excellent linearity (regression coefficient >0.999) and efficient recovery rates ranging from 95.98% to 109.57%. The method shows high sensitivity, with limits of detection and quantification of 0.25 and 0.5 ng/mL, respectively. The developed UHPLC–MS/MS method offers a simple, precise, accurate, and selective approach for monitoring NDMA levels in nizatidine formulations available in Australia, promising enhanced sensitivity and specificity with limits of quantification in the ppb and sub‐ppb ranges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, Gujarat, India.
- School of Applied Sciences and Technology, Gujarat Technological University, Ahmedabad, Gujarat, India.
ORCID-Profile: Janki Goswami, Bhumika Dudhatra, Kashyap Thummar
Förderung
- Gujarat Technological University
Zitieren
APA
Dhorajiya, S., Goswami, J., Dudhatra, B., & Thummar, K. (2024). Novel method for monitoring of carcinogenic impurity of N‐nitrosamine in nizatidine pharmaceutical products using ultra high‐pressure liquid chromatography triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.9884
Vancouver
Dhorajiya S, Goswami J, Dudhatra B, Thummar K. Novel method for monitoring of carcinogenic impurity of N‐nitrosamine in nizatidine pharmaceutical products using ultra high‐pressure liquid chromatography triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry. 2024. doi:10.1002/rcm.9884
BibTeX
@article{Dhorajiya2024,
author = {Dhorajiya, Shivani and Goswami, Janki and Dudhatra, Bhumika and Thummar, Kashyap},
title = {Novel method for monitoring of carcinogenic impurity of N‐nitrosamine in nizatidine pharmaceutical products using ultra high‐pressure liquid chromatography triple quadrupole mass spectrometry},
journal = {Rapid Communications in Mass Spectrometry},
year = {2024},
doi = {10.1002/rcm.9884}
}
EUVIMED